- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01527591
Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT)
Safety And Long-Term Immunogenicity Of The 13-Valent Pneumococcal Conjugate Vaccine In Children Who Are Solid Organ Transplant Recipients
Study Overview
Status
Intervention / Treatment
Detailed Description
The purpose of this study is to determine if a booster dose of 13-valent pneumococcal conjugate vaccine (PCV13) is safe and results in a measurable and durable immunologic response against pneumococcal subtypes present in the vaccine in solid organ transplant recipient (SOT) children.
Pneumococcal infections are amongst the most common infections seen in immunocompromised children. Infection by Streptococcus pneumoniae is one of the most frequently observed infection in immunocompromised children.
Pneumococcal polysaccharide vaccines (PPV) have been licensed in the U.S. for over 40 years. In contrast, pneumococcal conjugate vaccines are immunogenic and efficacious in normal infants and children, and offer hope of reducing pneumococcal infections in immunocompromised children. However, conjugate pneumococcal vaccine can only protect against a limited number of the 90 pneumococcal serotypes.
It is reasonable to anticipate that the introduction of PCV13 may help reduce the chances of severely immunocompromised children getting pneumococcal infections. Many of these children have been previously immunized with a full series of a 7-valent pneumococcal conjugate vaccine. These children will benefit from an additional dose of the new 13-valent vaccine. The degree to which SOT-recipient children are protected by prior immunizations and are responsive to new immunizations is still largely undefined. This study aims to expand the knowledge regarding the safety and immunogenicity of PCV13 immunization in this growing and vulnerable population.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095-1752
- UCLA
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Are 12 to 59 months of age.
- Have received a solid organ transplantation requiring ongoing immunosuppression.
- Have been receiving immunosuppressive agents for at least 3 months. Non-steroidal anti-inflammatory agents, G-CSF, erythropoietin and inhaled corticosteroids are not considered immunosuppressive agents for the purposes of this study.
- Expect to be able to complete the study injection and follow-up.
- Have parent or guardian's consent.
- Have received at least 3 doses of an approved PCV7 and/or PCV13 vaccine series.
Exclusion Criteria:
- Have received any inactivated vaccine within 4 weeks, or any live vaccine within 6 weeks of entering the study.
- Have had an allergic reaction or a serious side effect after receipt of any previous immunization to pneumococcal vaccines, or to other routine childhood immunizations.
- Have any other condition that would make receiving study vaccine inadvisable.
- Have other diseases of the immune system.
- Have any other disease or previous surgery that would interfere with study treatment.
- Are likely to have bleeding disorders.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: vaccine
pneumococcal conjugated vaccine
|
A single intramuscular dose of 0.5 mL.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To measure antibody concentrations by EIA and opsonophagocytosis assay (OPA)
Time Frame: Measured at different time points until 240 weeks post PCV 13 booster dose
|
Immunogenicity, functional antibody responses and sero-conversion will be evaluated by enzyme immunoassay (EIA) and opsonophagocytosis assay to a booster immunization with PCV13 vaccine in SOT-recipient children 12-59 months of age
|
Measured at different time points until 240 weeks post PCV 13 booster dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To measure the extent and persistence of immunity by measuring antibody concentrations by EIA and OPA
Time Frame: Measured at different time points until 240 weeks post PCV 13 booster dose
|
To measure the magnitude and persistence of humoral (EIA and OPA) anti--pneumococcal immune responses in children with SOT who were immunized with a booster dose of PCV 13 between 12 and 59 months of age
|
Measured at different time points until 240 weeks post PCV 13 booster dose
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jaime G Deville, MD, FAAP, University of California, Los Angeles
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pfizer-Prevnar13®
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infection in Solid Organ Transplant Recipients
-
Michael IsonViraCor LaboratoriesCompletedInfection in Solid Organ Transplant Recipients | Awaiting Organ TransplantUnited States
-
Nuria LloberasMinisterio de Sanidad, Servicios Sociales e IgualdadCompletedInfection in Solid Organ Transplant RecipientsSpain
-
Rabin Medical CenterCompletedInfection in Solid Organ Transplant RecipientsIsrael
-
Duke UniversityBaylor College of Medicine; Children's Hospital of Philadelphia; Albert Einstein... and other collaboratorsCompletedRespiratory Viral Infection | Infection in Solid Organ Transplant Recipients | Complications of Organ TransplantUnited States
-
Methodist Health SystemCompletedInfection in Solid Organ Transplant RecipientsUnited States
-
Oxford ImmunotecCompletedInfection in Solid Organ Transplant RecipientsUnited States, United Kingdom, Canada
-
National Institute of Allergy and Infectious Diseases...Clinical Trials in Organ Transplantation in ChildrenCompletedSolid Organ Transplant Recipients | Parent(s)/Guardian of Referenced Transplant RecipientsUnited States
-
Helio Tedesco Silva JuniorCompletedInfection in Solid Organ Transplant RecipientsBrazil
-
Paris Translational Research Center for Organ TransplantationCompletedOrgan Transplant Recipients
-
Bristol-Myers SquibbTerminatedImmunosuppression in Solid Organ TransplantFrance, Germany, Italy, United States, Austria, Canada, Spain, Argentina, Brazil
Clinical Trials on Pneumococcal Conjugate Vaccine 13 (PCV13)
-
Sinovac Life Sciences Co., Ltd.RecruitingPneumococcal InfectionsChina
-
St. Antonius HospitalCompletedPneumonia | Immune Response | Streptococcus PneumoniaeNetherlands
-
University of OxfordUniversity of Southampton; University of Bristol; University of LondonCompleted
-
Murdoch Childrens Research InstituteNational Health and Medical Research Council, Australia; GlaxoSmithKline; Bill... and other collaboratorsCompleted
-
Telethon Kids InstitutePapua New Guinea Institute of Medical ResearchCompleted
-
Aghia Sophia Children's Hospital of AthensUnknownImmunogenicity, Vaccine | Immunologic MemoryGreece
-
University of Witwatersrand, South AfricaUniversity College, LondonCompleted
-
London School of Hygiene and Tropical MedicineUniversity College, London; Bill and Melinda Gates Foundation; Wellcome Trust; KEMRI-Wellcome... and other collaboratorsActive, not recruitingPneumococcal Infection | Streptococcus Pneumoniae Infection | Invasive Pneumococcal Disease, Protection AgainstKenya
-
University of OxfordCompletedType 1 Diabetes MellitusUnited Kingdom
-
University of Toledo Health Science CampusNational Institute on Aging (NIA)Completed